Could a Drug in Clinical Trials Mean Breakthrough in Cancer Cachexia Treatment? | The Hormel Institute A new drug making its way through clinical trials shows promising options as a way to help patients manage cancer cachexia, which affects a person’s appetite and leads to the loss of fat and skeletal ...

#MedSky🧪 #Oncosky #pharmsky #immunosky #publichealth #Drugdiscovery Can Pfizer’s appetite-boosting antibody #ponsegromab address a cancer- #cachexia & help patients live longer in the process?
www.pfizer.com/news/article...

hi.umn.edu/news/could-d...

www.cancer.gov/news-events/...

Cancer Cachexia Market Expected to Grow at 8.9% CAGR from 2025 to 2034 The cancer cachexia market anticipates significant expansion, driven by innovative therapies and rising prevalence, projecting an 8.9% CAGR from 2025 to 2034.

Cancer Cachexia Market Expected to Grow at 8.9% CAGR from 2025 to 2034 #None #DelveInsight #cancer_cachexia #Ponsegromab

Το #ponsegromab για την καρκινική #καχεξία

Οι φαρμακευτικές #θεραπείες για την καρκινική καχεξία είναι περιορισμένες. Μια μελέτη φάσης 1b του μονοκλωνικού αντισώματος ponsegromab έδειξε βελτιωμένα αποτελέσματα σε #ασθενείς με αυξημένα επίπεδα της κυτοκίνης GDF-15. #καρκίνος #cancer #drugs #cahexia

Cancer Cachexia and the Brain Stem | NEJM The author describes the science behind a study of ponsegromab to treat cancer cachexia. Ponsegromab suppresses a pathway in neurons located in specific regions of the brain stem.

#MedSky🧪 #oncosky #skyRx #publichealth @nejm.org A report the results of a phase 2 #clinicaltrial of #ponsegromab therapy (100, 200, or 400 mg every 4 weeks) for #cancercachexia www.nejm.org/doi/pdf/10.1...